Trial Profile
A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR Study
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms STELLAR
- 19 Apr 2023 Primary endpoint has not been met. (Six-month progression-free survival(PFS-6),as per Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 06 Mar 2023 Status changed to discontinued.